SymBio Pharmaceuticals Limited (4582.T)
JPY 158.0
(0.64%)
JPY 158.0
(0.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.14 Billion JPY | 322.47% |
| 2022 | 1.92 Billion JPY | 12.88% |
| 2021 | 1.7 Billion JPY | 5.56% |
| 2020 | 1.61 Billion JPY | 85.09% |
| 2019 | 873.83 Million JPY | -34.67% |
| 2018 | 1.33 Billion JPY | 32.06% |
| 2017 | 1.01 Billion JPY | -27.31% |
| 2016 | 1.39 Billion JPY | 152.23% |
| 2015 | 552.47 Million JPY | 12.7% |
| 2014 | 490.22 Million JPY | 93.04% |
| 2013 | 253.95 Million JPY | -57.83% |
| 2012 | 602.23 Million JPY | -7.42% |
| 2011 | 650.53 Million JPY | 261.97% |
| 2010 | 179.71 Million JPY | -13.15% |
| 2009 | 206.93 Million JPY | 6.33% |
| 2008 | 194.61 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 910.3 Million JPY | 14.78% |
| 2024 Q1 | 718.35 Million JPY | -91.18% |
| 2024 Q2 | 793.1 Million JPY | 10.41% |
| 2023 FY | 8.14 Billion JPY | 322.47% |
| 2023 Q2 | 828.51 Million JPY | 0.65% |
| 2023 Q1 | 823.18 Million JPY | -57.29% |
| 2023 Q3 | 773.05 Million JPY | -6.69% |
| 2023 Q4 | 8.14 Billion JPY | 953.24% |
| 2022 Q2 | 1.17 Billion JPY | -16.94% |
| 2022 Q1 | 1.41 Billion JPY | -17.41% |
| 2022 FY | 1.92 Billion JPY | 12.88% |
| 2022 Q4 | 1.92 Billion JPY | 9.27% |
| 2022 Q3 | 1.76 Billion JPY | 50.59% |
| 2021 Q1 | 1 Billion JPY | -38.16% |
| 2021 FY | 1.7 Billion JPY | 5.56% |
| 2021 Q4 | 1.7 Billion JPY | 43.51% |
| 2021 Q3 | 1.18 Billion JPY | 14.11% |
| 2021 Q2 | 1.04 Billion JPY | 4.24% |
| 2020 Q3 | 1.23 Billion JPY | 55.94% |
| 2020 FY | 1.61 Billion JPY | 85.09% |
| 2020 Q4 | 1.61 Billion JPY | 30.8% |
| 2020 Q1 | 669.96 Million JPY | -23.33% |
| 2020 Q2 | 792.95 Million JPY | 18.36% |
| 2019 FY | 873.83 Million JPY | -34.67% |
| 2019 Q3 | 1.79 Billion JPY | 43.99% |
| 2019 Q1 | 1.05 Billion JPY | -21.39% |
| 2019 Q2 | 1.24 Billion JPY | 18.66% |
| 2019 Q4 | 873.83 Million JPY | -51.36% |
| 2018 Q4 | 1.33 Billion JPY | 62.87% |
| 2018 Q2 | 1.36 Billion JPY | 53.78% |
| 2018 Q1 | 888.46 Million JPY | -12.28% |
| 2018 FY | 1.33 Billion JPY | 32.06% |
| 2018 Q3 | 821.28 Million JPY | -39.89% |
| 2017 Q4 | 1.01 Billion JPY | -56.23% |
| 2017 FY | 1.01 Billion JPY | -27.31% |
| 2017 Q3 | 2.31 Billion JPY | 84.75% |
| 2017 Q2 | 1.25 Billion JPY | 21.88% |
| 2017 Q1 | 1.02 Billion JPY | -26.25% |
| 2016 FY | 1.39 Billion JPY | 152.23% |
| 2016 Q1 | 633.24 Million JPY | 14.62% |
| 2016 Q4 | 1.39 Billion JPY | 2.61% |
| 2016 Q3 | 1.35 Billion JPY | -33.68% |
| 2016 Q2 | 2.04 Billion JPY | 223.36% |
| 2015 FY | 552.47 Million JPY | 12.7% |
| 2015 Q3 | 182.58 Million JPY | -74.3% |
| 2015 Q4 | 552.47 Million JPY | 202.6% |
| 2015 Q2 | 710.33 Million JPY | 57.52% |
| 2015 Q1 | 450.94 Million JPY | -8.01% |
| 2014 Q3 | 263.96 Million JPY | -7.6% |
| 2014 Q2 | 285.68 Million JPY | -33.21% |
| 2014 FY | 490.22 Million JPY | 93.04% |
| 2014 Q1 | 427.74 Million JPY | 68.43% |
| 2014 Q4 | 490.22 Million JPY | 85.72% |
| 2013 Q3 | 208.65 Million JPY | -65.89% |
| 2013 Q4 | 253.95 Million JPY | 21.71% |
| 2013 FY | 253.95 Million JPY | -57.83% |
| 2013 Q1 | 610.78 Million JPY | 1.42% |
| 2013 Q2 | 611.76 Million JPY | 0.16% |
| 2012 FY | 602.23 Million JPY | -7.42% |
| 2012 Q1 | 740.67 Million JPY | 13.86% |
| 2012 Q2 | 636.81 Million JPY | -14.02% |
| 2012 Q3 | 280.67 Million JPY | -55.92% |
| 2012 Q4 | 602.23 Million JPY | 114.56% |
| 2011 Q2 | 729.45 Million JPY | 124.23% |
| 2011 Q3 | 426.1 Million JPY | -41.59% |
| 2011 Q4 | 650.53 Million JPY | 52.67% |
| 2011 FY | 650.53 Million JPY | 261.97% |
| 2011 Q1 | 325.31 Million JPY | 81.01% |
| 2010 FY | 179.71 Million JPY | -13.15% |
| 2010 Q4 | 179.71 Million JPY | 0.0% |
| 2010 Q2 | 133.64 Million JPY | 0.0% |
| 2009 Q4 | 206.93 Million JPY | 0.0% |
| 2009 Q2 | 147.88 Million JPY | 0.0% |
| 2009 FY | 206.93 Million JPY | 6.33% |
| 2008 Q4 | 194.61 Million JPY | 0.0% |
| 2008 FY | 194.61 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 67.416% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.896% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 98.916% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 95.046% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -139.829% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 81.006% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 70.781% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 98.355% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | -61.55% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 86.802% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 73.592% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 79.539% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 73.806% |
| Tsumura & Co. | 132.88 Billion JPY | 93.873% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 79.538% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 38.767% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 97.037% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 81.561% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 88.484% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 82.637% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | -16.266% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 67.993% |
| MedRx Co., Ltd | 129 Million JPY | -6211.733% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -148.802% |
| Solasia Pharma K.K. | 673 Million JPY | -1109.827% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -1161.363% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 74.054% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 95.035% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -705.084% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 98.446% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | -17.114% |